Drug intelligence / Profile preview

LD01161

Development stage: Preclinical
Lead developer: Shanghai Leado Pharmatech
Modality: Small Molecules
Administration: Oral

Overview

LD01161 is a small molecule drug candidate developed by Leado Pharma (Shanghai Leado Pharma Technology) for the treatment of refractory epilepsy. The drug is currently in the IND-enabling stage of development. Leado Pharma focuses on the research and development of innovative drugs targeting ion channels, utilizing their proprietary platform to identify modulators for various neurological and pain-related conditions. LD01161 is intended to provide a new therapeutic option for patients whose seizures are not adequately controlled by existing anti-epileptic drugs. The specific molecular target and mechanism of action for LD01161 have not yet been publicly disclosed by the company.

Other names: LD01161LD-01161LD 01161

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on LD01161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LD01161.

Explore the full profile